Sezione di Gastroenterologia & Epatologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy.
Ann Oncol. 2013 Apr;24 Suppl 2:ii30-7. doi: 10.1093/annonc/mdt055.
Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patients with well-preserved liver function (Child-Pugh A class) and advanced-stage HCC (BCLC-C) or in patients with HCC progressing after locoregional therapies, with a high grade of recommendation. The approval of sorafenib for this indication was grounded on the efficacy and the safety results reported by two international randomized, controlled trials, the SHARP and the Asia-Pacific studies. In addition, the efficacy and the safety of sorafenib in clinical practice are addressed by several field-practice experiences, including the multinational GIDEON study and the SOFIA study. Finally, further research on sorafenib is ongoing to optimize the use of this molecule. This review aims to provide an overview of the most relevant clinical data on the efficacy and the safety of sorafenib in patients with HCC.
索拉非尼被认为是肝功能良好（Child-Pugh A 级）和晚期 HCC（BCLC-C）患者或局部区域治疗后进展的 HCC 患者的标准系统治疗药物，具有高度推荐等级。索拉非尼在该适应证中的获批基于两项国际随机对照试验（SHARP 和亚太研究）报告的疗效和安全性结果。此外，几项临床实践经验，包括多国 GIDEON 研究和 SOFIA 研究，也涉及了索拉非尼的疗效和安全性。最后，正在进行关于索拉非尼的进一步研究，以优化这种分子的使用。本文旨在综述索拉非尼在 HCC 患者中的疗效和安全性的最相关临床数据。
